Decision to list urology, ostomy and continence products supplied by Jackson Allison Medical & Surgical Limited

2 September 2019

Hospital devices Decision

We are pleased to announce the approval of a non-exclusive listing agreement with Jackson Allison Medical & Surgical Limited for the supply of urology, ostomy and continence, products.

This will result in 93 of Jackson Allison’s urology, ostomy and continence products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 October 2019.

DHBs will be able to continue to purchase other suppliers’ brands of urology, ostomy and continence products as the agreement is not for sole supply.

Any changes to the original proposal?

This decision was subject to a consultation letter dated 25 July 2019

No changes have been made to the agreement as a result of the consultation feedback.

Who we think will be most interested

Suppliers and Wholesalers
DHB Staff
- clinical staff in a range of inpatient, outpatient and community settings where continence products are used
- procurement and supply chain personnel

Detail about this decision

In May 2018, PHARMAC issued a request for proposals (“RFP”) for the supply of urology, ostomy and continence products to DHBs

The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After evaluating Jackson Allison’s proposal, and consulting on the provisional agreement reached, PHARMAC has decided to list Jackson Allison’s urology ostomy and continence products, in Part III of Section H of the Pharmaceutical Schedule from 1 October 2019.

The list of products will be available on PHARMAC’s website from 1 October 2019, in both a PDF document and an Excel spreadsheet

Our response to what you told us

We appreciate the time people took to respond to this consultation.

All consultation responses received by 15 August 2019 were considered in their entirety in making the decision to approve this agreement.

A summary of the main themes raised in feedback and our responses to the feedback are set out below:

Theme	PHARMAC comment
No technical or resource impacts are expected as a result of the proposal.	Noted.
A DHB clinician asked for clarification about the number of suppliers that would be needed to supply DHBs with urology, ostomy and continence devices, noting that it can be complicated and expensive to maintain access to more devices than are clinically required.	DHBs use a wide range of urology, ostomy and continence devices and, under its current phase of work, PHARMAC is aiming to populate the Pharmaceutical Schedule with the types of devices that DHBs use. DHBs can choose which devices they purchase and are under no obligation to purchase the listed urology, ostomy and continence devices. Once the Pharmaceutical Schedule is fully populated, PHARMAC expects to make some of the standardisation decisions that individual DHBs currently make however the range of medical devices on the Pharmaceutical Schedule needs to be wide enough to meet the needs of patients across all DHBs.

Theme

PHARMAC comment

No technical or resource impacts are expected as a result of the proposal.

Noted.

A DHB clinician asked for clarification about the number of suppliers that would be needed to supply DHBs with urology, ostomy and continence devices, noting that it can be complicated and expensive to maintain access to more devices than are clinically required.

DHBs use a wide range of urology, ostomy and continence devices and, under its current phase of work, PHARMAC is aiming to populate the Pharmaceutical Schedule with the types of devices that DHBs use.

DHBs can choose which devices they purchase and are under no obligation to purchase the listed urology, ostomy and continence devices.

Once the Pharmaceutical Schedule is fully populated, PHARMAC expects to make some of the standardisation decisions that individual DHBs currently make however the range of medical devices on the Pharmaceutical Schedule needs to be wide enough to meet the needs of patients across all DHBs.

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.